A small-molecule IRF3 agonist functions as an influenza vaccine adjuvant by modulating the antiviral immune response (Q30399737)

21 June 2017

title

A small-molecule IRF3 agonist functions as an influenza vaccine adjuvant by modulating the antiviral immune response (English)

1 reference

21 June 2017

1 reference

Peter Probst

1

1 reference

21 June 2017

John B Grigg

2

1 reference

21 June 2017

Myra Wang

3

1 reference

21 June 2017

Ernesto Muñoz

4

1 reference

21 June 2017

Yueh-Ming Loo

5

1 reference

21 June 2017

Renee C Ireton

6

1 reference

21 June 2017

Michael Gale

7

1 reference

21 June 2017

Shawn P Iadonato

8

1 reference

21 June 2017

Kristin M Bedard

9

1 reference

21 June 2017

language of work or name

English

0 references

publication date

6 March 2017

1 reference

21 June 2017

number of pages

8

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

21 June 2017

volume

35

1 reference

21 June 2017

issue

15

1 reference

21 June 2017

page(s)

1964-1971

1 reference

Estimates of US influenza-associated deaths made using four different methods

21 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.01.053

Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.01.053

RIG-I in RNA virus recognition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.01.053

Immune signaling by RIG-I-like receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.01.053

Emerging complexity and new roles for the RIG-I-like receptors in innate antiviral immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.01.053

A Sendai virus-derived RNA agonist of RIG-I as a virus vaccine adjuvant.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.01.053

Activation of the RIG-I pathway during influenza vaccination enhances the germinal center reaction, promotes T follicular helper cell induction, and provides a dose-sparing effect and protective immunity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.01.053

Isoflavone agonists of IRF-3 dependent signaling have antiviral activity against RNA viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.01.053

Regulating intracellular antiviral defense and permissiveness to hepatitis C virus RNA replication through a cellular RNA helicase, RIG-I

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.01.053

Sensitivity and specificity of serologic assays for detection of human infection with 2009 pandemic H1N1 virus in U.S. populations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.01.053

Systematic identification of small molecule adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.01.053

Rational design of small molecules as vaccine adjuvants.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.01.053

Coexpressed RIG-I agonist enhances humoral immune response to influenza virus DNA vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.01.053

The chemotherapeutic agent DMXAA as a unique IRF3-dependent type-2 vaccine adjuvant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.01.053

Virally delivered cytokines alter the immune response to future lung infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.01.053

Intranasal delivery of whole influenza vaccine prevents subsequent allergen-induced sensitization and airway hyper-reactivity in mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.01.053

Intranasal influenza vaccination using a new synthetic mucosal adjuvant SF-10: induction of potent local and systemic immunity with balanced Th1 and Th2 responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.01.053

New paradigms in type 2 immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.01.053

Evolution of Th2 immunity: a rapid repair response to tissue destructive pathogens.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.01.053

10.1016/J.VACCINE.2017.01.053

7 January 2021

Identifiers

DOI

1 reference

21 June 2017

1 reference